Raymond James & Associates trimmed its position in Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 9.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 138,091 shares of the company’s stock after selling 14,374 shares during the period. Raymond James & Associates owned approximately 0.31% of Omnicell worth $6,963,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of OMCL. MetLife Investment Management LLC grew its position in Omnicell by 55.4% in the 1st quarter. MetLife Investment Management LLC now owns 23,169 shares of the company’s stock valued at $3,000,000 after buying an additional 8,257 shares during the last quarter. Rhumbline Advisers lifted its holdings in Omnicell by 6.4% in the first quarter. Rhumbline Advisers now owns 111,098 shares of the company’s stock valued at $14,386,000 after acquiring an additional 6,657 shares during the period. Great West Life Assurance Co. Can lifted its holdings in Omnicell by 0.4% in the first quarter. Great West Life Assurance Co. Can now owns 37,956 shares of the company’s stock valued at $5,036,000 after acquiring an additional 144 shares during the period. Raymond James Trust N.A. lifted its holdings in Omnicell by 10.9% in the first quarter. Raymond James Trust N.A. now owns 3,881 shares of the company’s stock valued at $503,000 after acquiring an additional 382 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in Omnicell by 0.6% in the first quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock valued at $109,901,000 after acquiring an additional 4,839 shares during the period.
Omnicell Trading Up 0.2 %
Shares of OMCL stock opened at $73.36 on Friday. The firm has a 50-day moving average price of $60.88 and a 200 day moving average price of $55.48. Omnicell, Inc. has a twelve month low of $46.11 and a twelve month high of $125.17. The company has a market capitalization of $3.31 billion, a price-to-earnings ratio of -183.40, a PEG ratio of 10.61 and a beta of 0.90. The company has a current ratio of 2.06, a quick ratio of 1.75 and a debt-to-equity ratio of 0.50.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on OMCL shares. Piper Sandler raised their target price on Omnicell from $55.00 to $66.00 and gave the company an “overweight” rating in a report on Friday, January 27th. SVB Leerink reissued a “market perform” rating on shares of Omnicell in a report on Friday, January 27th. Benchmark raised Omnicell from a “hold” rating to a “buy” rating and set a $68.00 target price for the company in a report on Monday, February 27th. Wells Fargo & Company cut their price target on Omnicell from $71.00 to $65.00 and set an “overweight” rating for the company in a research note on Tuesday, January 24th. Finally, StockNews.com initiated coverage on Omnicell in a research note on Thursday. They set a “hold” rating for the company. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Omnicell currently has an average rating of “Moderate Buy” and an average target price of $72.22.
Insider Activity at Omnicell
In related news, Director Joanne B. Bauer sold 13,115 shares of the business’s stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $54.24, for a total value of $711,357.60. Following the completion of the transaction, the director now owns 28,096 shares of the company’s stock, valued at approximately $1,523,927.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.76% of the stock is currently owned by corporate insiders.
Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.
- Get a free copy of the StockNews.com research report on Omnicell (OMCL)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.